European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups. It ...

The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported ...

The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported ...